As Ozempic and other GLP-1 drugs explode in popularity, driven by their off-label use for rapid weight loss and viral social media trends, the pharmaceutical industry faces unprecedented challenges.
According to a letter (PDF) signed by US Senators Elizabeth Warren (D-Mass), Angela Alsobrooks (D-Md), Richard Blumenthal ...
Novartis has claimed accelerated approval from the FDA for Vanrafia, one of a trio of therapies it hopes will revolutionise the treatment of rare kidney disease IgA nephropathy (IgAN). Vanrafia ...
A woman from the Wirral in the UK has become the first patient in the world to receive an experimental cancer vaccine ...
Hogan Lovells partner Alice Valder Curran returned to join pharmaphorum editor-in-chief Jonah Comstock to elucidate some of ...
Today, the EU Council and Parliament reached an agreement in principle on the long-awaited pharma reform package, but Europe's drug industry has already said it will not be enough to keep the sector ...
Two months after saying it couldn't recommend Genmab's cervical cancer therapy Tivdak for use by the NHS, reimbursement authority NICE has had a change of heart. In final draft guidance (PDF), NICE ...
Scribe Therapeutics has become the latest biotech to list on the Nasdaq in the US, raising more than $155 million to advance ...
AstraZeneca and Daiichi Sankyo's TROP2-targeting drug Datroway has been approved by the European Commission for some previously untreated patients with metastatic triple-negative breast cancer (TNBC), ...
Moreover, there are blood tests based on biomarkers that measure the body's immune response to infection, such as the Qiagen ...
A dual GLP-1 and glucagon agonist developed by Altimmune has been shown to reduce drinking in people with alcohol use ...
AbbVie's fast-growing JAK inhibitor Rinvoq has been cleared for alopecia areata in the EU, the first market for the hair loss ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results